GlassScriptPhysician profile
Chao Vang
NPI 1578568069
$5,103.10
in general payments reported to CMS, 2019-2025
31 companies · $881 in 2025
The $881 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $565 · 2022: $995 · 2023: $1,833 · 2024: $829 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,484 · Travel and Lodging: $760 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,484.20 |
| Travel and Lodging | $760.40 |
| Education | $297.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $969.92 | 2023 | Interstim |
| Astellas Pharma US INC | $963.44 | 2021-2025 | Xtandi, Myrbetriq, Veozah |
| Sumitomo Pharma America, INC. | $787.74 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $429.04 | 2021-2025 | Erleada |
| Urovant Sciences INC | $361.00 | 2022 | |
| Boston Scientific Corporation | $248.65 | 2022-2024 | Lithovue, Ams 700 |
| Abbvie INC. | $234.60 | 2021-2025 | |
| Antares Pharma, INC. | $211.40 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Coloplast Corp | $100.16 | 2021-2025 | |
| Dendreon Pharmaceuticals LLC | $88.56 | 2021-2024 | Provenge |
| Tolmar Pharmaceuticals, INC. | $71.47 | 2021-2022 | |
| Allergan, INC. | $57.14 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $54.51 | 2023-2025 | Bard Urinary Drainage Bag |
| Tolmar, INC. | $50.36 | 2023 | |
| Pfizer INC. | $50.01 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $48.11 | 2021-2022 | |
| Angiodynamics, INC. | $48.07 | 2021 | |
| Halozyme INC | $41.94 | 2023 | |
| Merck Sharp & Dohme LLC | $39.85 | 2023-2025 | Keytruda, Lynparza |
| Endo USA, INC. | $39.77 | 2025 | Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $27.11 | 2025 | |
| Olympus America INC. | $23.49 | 2024 | Itind System |
| Procept Biorobotics Corporation | $23.15 | 2023 | Aquabeam Robotic System |
| 180 Medical, INC. | $20.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.38 | 2024 | |
| Karl Storz Endoscopy-America | $17.87 | 2024 | N.A. |
| Ambu INC. | $16.39 | 2022 | |
| Endo Pharmaceuticals INC. | $16.11 | 2021 | |
| Davol INC. | $15.73 | 2025 | Arista |
| Axonics, INC. | $13.89 | 2021 | |
| Sobi, INC | $13.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chao Vang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.